The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSALV.L Regulatory News (SALV)

  • There is currently no data for SALV

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of EGM and Shareholder Circular

27 Mar 2013 07:00

RNS Number : 9537A
3Legs Resources plc
27 March 2013
 



For Immediate Release

 

27 March 2013

 

 

3Legs Resources plc

 

3Legs Resources plc ("3Legs" or the "Company") announces details of an Extraordinary General Meeting and the posting of a Circular to Shareholders

 

The Board unanimously recommends Shareholders to vote AGAINST all proposed resolutions

 

Following the request from Singer Nominees Limited, as nominee for Damille Investments II Limited ("Damille"), to convene an extraordinary general meeting (the "Extraordinary General Meeting" or the "EGM") to propose resolutions (the "EGM Resolutions") for the removal of four of the six existing Directors, the appointment of two representatives of Damille as Directors and the adoption of a new investment objective for the Company, namely, to manage the realisation of the Company's existing assets and to restrict new investments by the Company, the Company yesterday posted to Shareholders a Notice of Extraordinary General Meeting and a Circular containing the 3Legs' Board of Directors' recommendation to vote against the EGM Resolutions and its reasons for such recommendation.

 

The Board unanimously recommends that Shareholders vote AGAINST all of the EGM Resolutions for the following reasons:

 

The Board firmly believes that there is significant value to be unlocked in the Company's Baltic Basin concessions. The Board is focussed on two key areas:

 

1) Maximising the potential and value of the Baltic Basin concessions

a. Pursuing the planned drilling and testing programme over the next year, investing alongside our co-venture partner ConocoPhillips, one of the world's largest publicly quoted oil and gas companies;

b. Retaining sufficient technical and operating capability to enable us to make informed decisions to properly manage our interest in the Baltic Basin concessions;

c. Maintaining the local and industry relationships necessary to successfully progress a Polish shale venture.

2) Minimising the Company's costs; our current cash balance is a key asset and will be deployed prudently

a. Cessation of pursuing new ventures; and

b. Reduction of cash G&A costs by approximately 50%, so that our focus is purely on unlocking the upside potential of our Baltic Basin concessions.

 

The Board believes this strategy offers Shareholders the greatest chance of realising the upside potential from the Baltic Basin concessions whilst preserving cash. Following the planned drilling programme (estimated cost £11 million), the Company will review its Polish operations and, in light of the results, consider all options, including a return to Shareholders of the remaining cash (currently projected to be approximately £26 million as at 30 June 2014).

 

Furthermore, if shareholders choose to vote for the EGM Resolutions proposed by Damille, the Board:

 

1) Has concerns over whether Damille's representatives have any interest in retaining the Baltic Basin concessions. The Board believes that:

a. Damille does not have the desire to understand and unlock the value from the Baltic Basin concessions; and

b. Damille will focus on winding down operations of the Company and returning cash to shareholders, as it has done before in a number of similar situations.

2) Does not believe that the Damille representatives have the experience required to unlock the potential of the Baltic Basin concessions. The Board:

a. Has seen no evidence that Damille's representatives have any shale gas experience; and

b. Does not believe that Damille's representatives have the relationships required to pursue oil and gas operations in Poland.

Damille and its supporters are seeking to change the strategic direction of the Company without paying any control premium to do so.

 

The Board has received expressions of support from Shareholders representing approximately 48.5 per cent. of the Company's issued share capital indicating that they intend to vote AGAINST the EGM Resolutions. These Shareholders include institutions (BlackRock, J P Morgan Natural Resource Funds, Jupiter Asset Management and M&G); Directors; management; and founders of the Company (including Caithness Limited, as trustee for Robert Jeffcock). Robert Jeffcock initially identified the potential of the Baltic Basin and was the driving force behind the founding of the Company.

 

The Extraordinary General Meeting will be held at Mount Murray Hotel, Mount Murray Road, Santon, Isle of Man, IM4 2HT on 19th April 2013 at 12.30 p.m. (or as soon thereafter as the Annual General Meeting has concluded).

 

The Circular and Notice of Extraordinary General Meeting are also available to view on the Company's website (www.3legsresources.com).

For further information contact:

 

3Legs Resources plc

Tel:

+44 1624 811 611

Kamlesh Parmar, CEO

Alexander Fraser, CFO

Jefferies Hoare Govett

Tel:

+44 207 029 8000

Simon Hardy

Jamie Buckland

Jason Grossman

Northland Capital Partners

Tel:

+44 207 796 8800

Louis Castro

Matthew Johnson

College Hill

Tel:

+44 207 457 2020

Matthew Tyler

Catherine Wickman

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMMGZFLVVGFZM
Date   Source Headline
9th Jan 20202:30 pmRNSCancellation of trading on AIM
20th Dec 201910:30 amRNSCancellation of AIM listing /Potential acquisition
27th Sep 201911:07 amRNSHalf-year Report - Correction
26th Sep 20192:06 pmRNSHalf-year Report
23rd Sep 20193:02 pmRNSAIM Rule 17 Notification
9th Jul 20197:30 amRNSSuspension - SalvaRx Group Plc
9th Jul 20197:30 amRNSSuspension of Trading
28th Jun 201911:26 amRNSFinal Results
31st Jan 20197:00 amRNSChange of Nominated Adviser and Broker
17th Jan 20192:05 pmRNSSecond Price Monitoring Extn
17th Jan 20192:00 pmRNSPrice Monitoring Extension
8th Jan 20194:15 pmRNSResult of AGM and Completion of Disposal
4th Jan 20195:30 pmRNSSalvarx Group
14th Dec 20187:50 amRNSNominated Adviser Status
10th Dec 20187:00 amRNSIssue of US$1 million of Loan Notes by iOx
27th Nov 20187:00 amRNSPosting of Circular and Notice of AGM
21st Nov 20181:00 pmRNSTransaction Update
6th Nov 20187:00 amRNSDirector/PDMR Dealing
22nd Oct 20189:47 amRNSIntensity Therapeutics Update
9th Oct 20187:00 amRNSExercise of Warrants
27th Sep 20187:00 amRNSHalf-year Report
28th Aug 20185:40 pmRNSUpdate re proposed disposal and demerger
14th Aug 20187:00 amRNSProposed disposal of interest in SalvaRx Limited
1st Aug 20184:40 pmRNSSecond Price Monitoring Extn
1st Aug 20184:35 pmRNSPrice Monitoring Extension
23rd Jul 20181:17 pmRNSDelay in iOx development programme
28th Jun 20187:00 amRNSFinal Results
26th Jun 20187:00 amRNSRelated Party Loan of US$1 million
8th Mar 201812:00 pmRNSDrug Pipeline Progress and iOx Loan Note Issue
30th Oct 20174:40 pmRNSSecond Price Monitoring Extn
30th Oct 20174:35 pmRNSPrice Monitoring Extension
23rd Oct 20177:00 amRNSSubscriptions for SalvaRx Ltd Loan Facility
27th Sep 20179:00 amRNSHalf-year Report
25th Sep 20178:00 amRNSFormation of Saugatuck Therapeutics
1st Aug 20173:30 pmRNSHolding(s) in Company
1st Aug 20173:30 pmRNSHolding(s) in Company
31st Jul 20171:45 pmRNSResult of AGM
5th Jul 20173:03 pmRNSNotice of AGM
30th Jun 20178:34 amRNSFinal Results
30th May 201712:45 pmRNSIntensity Therapeutics Treats First Patient
20th Mar 20177:00 amRNSInvestment in Rift Biotherapeutics
2nd Mar 20177:00 amRNSRestructuring, Loan Conversion and Loan Facility
28th Feb 20177:00 amRNSInvestment in Nekonal
2nd Feb 20174:37 pmRNSIntensity Therapeutics
3rd Oct 20164:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20164:35 pmRNSPrice Monitoring Extension
14th Sep 20167:00 amRNSCorporate Video
13th Sep 20167:00 amRNSHalf-year Report
22nd Aug 20167:00 amRNSDrug Pipeline Progress including Patent Grants
4th Aug 20162:05 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.